Journal article
Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T2 relaxometry pilot study
SJ Wood, L Cocchi, TM Proffitt, M McConchie, GD Jackson, T Takahashi, C Pantelis, PD McGorry, GE Berger
Psychiatry Research Neuroimaging | Published : 2010
Abstract
We used magnetic resonance imaging to examine the effect of ethyl-eicosapentaenoic acid (E-EPA) on hippocampal T2 relaxation time in first episode psychosis patients at baseline and after 12weeks of follow-up. There was an increase in T2 in the placebo group but not in the E-EPA group, suggesting a neuroprotective effect of E-EPA treatment. In addition, the smaller the increase in T2, the greater the improvement in negative symptoms. © 2009 Elsevier Ireland Ltd.
Related Projects (1)
Grants
Awarded by Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Funding Acknowledgements
This work was supported by two NH&MRC project grants (ID. 145627; 209062), a NH&MRC program grant (ID: 350241), and the Colonial Foundation, Melbourne, Australia A/Prof Wood is supported by a Clinical Career Development Award from the NH&MRC, and Dr Cocchi by a Swiss National Science Foundation young investigator award (PBLAB3-119622). A Margaret & Walter Lichtenstein Foundation award (University of Basel) supported Dr Berger. These funding sources had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. None of the authors has a conflict of interest with any manufacturer or distributor of omega-3 fatty acids. The presented data were part of an investigator-initiated Laxdale Ltd (now owned by Amarin Corporation) provided the study medication for free. None of the research centres received any financial support from Laxdale Ltd.